|
|
|
CLSD - Clearside Biomedical, Inc
Clearside Biomedical Inc (CLSD) is a biopharmaceutical company based in Georgia, USA. The company's primary focus is on developing and commercializing innovative therapies to treat ocular diseases. Its proprietary SCS Microinjector(R) technology is designed to deliver therapeutic agents to the back of the eye, where they are needed most.
Clearside's lead product, XIPERE (triamcinolone acetonide ophthalmic suspension), was approved by the U.S. Food and Drug Administration (FDA) in October 2019 for the treatment of macular edema associated with uveitis, a condition that can lead to blindness. XIPERE is administered via the SCS Microinjector(R) technology and is designed to reduce the need for frequent injections, a significant advantage for patients.
Clearside is also developing other product candidates using its SCS Microinjector(R) technology, including suprachoroidal CLS-TA for the treatment of macular edema associated with retinal vein occlusion and suprachoroidal CLS-AX for the treatment of wet age-related macular degeneration.
The company is committed to advancing its proprietary technology to improve the lives of patients with ocular diseases. Clearside has collaborations with industry leaders, including Bausch Health, Aura Biosciences, REGENXBIO, and Santen Pharmaceutical, to develop and commercialize innovative therapies for ocular diseases.
As of February 18, 2023, Clearside Biomedical Inc (CLSD) had a market capitalization of approximately $123 million.
|
|
|
|
|
